Rising Cases Of Peripheral Artery Disease Fueling The Growth Of The Market Due To Increasing Prevalence And Risk Factors: Key Factor Driving The Growth In The Intermittent Claudication Market

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Expected Intermittent Claudication Market Size During the Forecast Period?
The market size for intermittent claudication has seen robust growth in the past few years. It is predicted to expand from $12.81 billion in 2024 to $13.64 billion in 2025, yielding a compound annual growth rate (CAGR) of 6.5%. The historical growth is credited to the increasing number of peripheral artery disease cases, heightened awareness of vascular diseases, a growing elderly population, enhanced diagnostic rates, and escalated healthcare expenditure.

Expectations for the intermittent claudication market size point towards considerable growth in the coming years. The market is projected to be valued at $17.39 billion in 2029, with a compound annual growth rate (CAGR) of 6.2%. This market expansion through the forecast period is linked to the increasing incidence of diabetes, growing obesity rates, the upward trend in cardiovascular diseases, increasing alcohol and tobacco consumption, and an uptick in healthcare expenditure. Key market trends anticipated in the forecast period consist of progress in pad diagnostics, an increase in the use of wearable devices, the incorporation of personalized medicine, a move towards drug-eluting stents, and advancements in the field of stem cell therapy.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22021

What Are the High-Growth Segments in the Intermittent Claudication Market?
The intermittent claudication market covered in this report is segmented -

1) By Type: Medication Therapies, Revascularization
2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration
3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline
2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp

What Key Drivers Are Expected to Influence Future Intermittent Claudication Market Growth?
The surge in instances of peripheral artery disease (PAD) is predicted to drive the progression of the intermittent claudication market in the future. PAD is a circulatory issue in which constricted arteries lessen the blood flow to the limbs, leading to pain, numbness, and additional problems. The rising instances of peripheral artery disease can be traced back to factors such as an aging populace, diabetes, smoking, high blood pressure, obesity, and inactive lifestyle habits. PAD triggers intermittent claudication by hindering the blood flow to the leg muscles whilst exercising, which consequently results in pain and muscle cramps due to lack of oxygen. For example, a report by the American Heart Association Journals, a peer-reviewed open-access scientific journal based in the U.S., stated in June 2023 that PAD affects between 7-12 million individuals in the U.S., and 200 million worldwide. Hence, the surging instances of peripheral artery disease (PAD) are fostering the expansion of the intermittent claudication market.

Which Companies Hold the Largest Share Across Different Intermittent Claudication Market Segments?
Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, Pharmacompass.

What Trends Are Driving Growth in The Intermittent Claudication Market?
Leading firms in the intermittent claudication market are turning their attention to innovative medicinal therapies like RIPK1 inhibitors to improve the results of treatments given to patients diagnosed with peripheral artery disease (PAD) with intermittent claudication. The goal is to enhance blood circulation, reduce inflammation, and halt the progression of the disease. RIPK1 inhibitors are specialized medications designed to suppress RIPK1 kinase activity, which in turn reduces inflammation and cell death. For example, GenFleet, a biotech company situated in China, was granted approval by the US FDA in August 2022 to carry out a Phase II clinical trial of GFH312. This innovative therapy targets PAD with intermittent claudication (IC). The study, which is randomized, double-blinded, and placebo-controlled, will take place at 15 different research centres. In animal model preclinical studies, GFH312, a RIPK1 inhibitor, has demonstrated potential by reducing the inflammatory response.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report

What Are the Emerging Geographies for The Intermittent Claudication Market Growth?
North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Intermittent Claudication Market?
2. What is the CAGR expected in the Intermittent Claudication Market?
3. What Are the Key Innovations Transforming the Intermittent Claudication Industry?
4. Which Region Is Leading the Intermittent Claudication Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.